Council of Scientific & Industrial Research (CSIR) Current Affairs - 2020
On May 8, 2020, the Council of Scientific and Industrial Research (CSIR) begins its clinical trials on Favipiravir and Phytopharmaceutical.
Apart from Favipiravir and Phytopharmaceutical, the CSIR is also working on native herbs as biological medicine. The DGCI (Drug Controller General of India) has approved the clinical trials to be conducted by the CSIR.
Favipiravir is commonly used in China and Japan and also in other countries to treat influenza.
Apart from the two medicines, the CSIR is also trying several other drugs. In May 2016, the pharmaceutical company ICCGEB (International Centre for Genetic Engineering and Biotechnology), Delhi had signed agreement to develop botanical drug to treat dengue. The efficacy of this medicine in treating COVID-19 is almost similar. The drug is already in phase II of human trial.
The clinical trial of Favipiravir is to be completed in about one and half months. If the tests are successful, the drugs are to be available at affordable prices.
Tags: China • Clinical trials • Council of Scientific & Industrial Research (CSIR) • COVID-19 • CSIR
On April 18, 2020, the Council of Scientific and Industrial Research (CSIR)-National Aerospace Laboratories (NAL) developed Personal Protective Cover all suit. The suit has been produced with polypropylene spun multilayered non-woven fabric.
The Polypropylene spun suit can be used to ensure safety of doctors, paramedical staff, health care workers and nurses. The CSIR-NAL is to produce 30,000 suits per day. The main benefit of the suit is that it is competitive in prices as compared to other suits that are being imported.
It is to be noted that China sent 1,70,000 Personal Protection Equipment (PPE) kits. Of these around 50,000 failed to pass safety tests conducted by DRDO. In order to avoid these situations, it is important to boost PPE manufactured in locally.
India is currently importing PPE from Singapore, China. India has also banned the export of PPE to avoid shortage of PPE kits in the country.